SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SCIO Scios Inc.
SCIO 0.010000.0%Aug 19 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (1380)5/30/2001 12:00:48 AM
From: Miljenko Zuanic  Read Replies (1) of 1477
 
<<I agree that NG may not be the universal standard of care, but it was what the FDA asked SCIO to compare with Natrecor.>>

Peter,

At previous AC meeting MDs (AC panelists) main reason (in addition to N safety concern) for pissing on Natrecor was NTG *golden efficacy*. VMAC trial throw shit on their face, because NTG didn't do better than placebo.

NTG comparison was MD-expert recommendation.

Robert's position is just *echo* from first AC panelist.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News